Design, Synthesis and anti microbial, anti-inflammatory, Antitubercular activities of some 2,4,5-trisubstituted imidazole derivatives.

 

R. S. Kalkotwar1* and R. B. Saudagar2

1Department of  Pharmaceutical Sciences, Bhagwant University, Ajmer, Rajashthan, India

2Department of  Pharmaceutical Chemistry, R.G. Sapkal College of  Pharmacy, Nashik, M.S. India.

*Corresponding Author E-mail: rsk_55@rediffmail.com.

 

 

ABSTRACT:

A Novel Series of Some 2,4,5-trisubstituted imidazole derivatives were prepared with the aim to get better antibacterial activity, antifungal activity, antitubercular and anti-inflammatory activity. The structures of synthesized compounds were supported by means of IR, 1H NMR. Title compounds were evaluated for antibacterial activity, antifungal activity, antitubercular and anti-inflammatory activities. Among the synthesized compounds some compounds found to possess all these activities. The QSAR study for anti-inflammatory activity shows good results.

 

KEYWORDS: QSAR, Antibacterial, antifungal, anti-inflammatory activity.

 


INTRODUCTION:

Imidazole derivatives are of wide interest because of their diverse biological activity and clinical applications, they are remarkably effective compounds both with respect to their inhibitory activity and their favorable selectivity ratio. Imidazole are regarded as a promising class of bioactive heterocyclic compounds that exhibit a range of biological activities. This ring system is present in numerous antioxidant, antiparasitic, antihelmintics, antiproliferative, anti-HIV, anticonvulsant, anti-inflammatory, antihypertensive, antineoplastic and antitrichinellosis activities. Varied bioactivities exhibited by Imidazole, efforts have been made from time to time to generate libraries of these compounds and screened them for potential biological activities. Also it is well documented that imidazole nucleus is associated with a variety of pharmacological actions. It displays pronounced anticonvulsant, antifungal and antimycobacterial activities. Extensive biochemical and pharmacological studies have confirmed that imidazole molecules are effective against various strains of microorganisms.

 

Imidazole are regarded as a promising class of bioactive heterocyclic compounds that exhibit a range of biological activities. Looking at the importance of imidazole nucleus, it was thought that it would be worthwhile to design and synthesize some new imidazole derivatives and screen them for potential biological activities.

 

MATERIALS AND METHODS:

Melting points were determined in open capillary method and are uncorrected. The 1H-NMR spectra were recorded on sophisticated multinuclear FT-NMR Spec-trometer model Advance-II (Bruker) using dimethylsulfoxide-d6 as solvent and tetramethylsilane as internal standard. IR spectra were recorded on Thermo Nicolet IR 200 spectrophotometer using KBr disc method. Biological activity (anti-inflammatory activity) values are reported as inhibitory activity on Carrageenan induced rat paw oedema (% inhibition at 2 hr). Pharmacological screening values were by converted into Log (% Inh) were used for multiple correlation analysis with descriptors generated using TSAR 3.3 software.

 

QSAR METHODOLOGY

All molecules were drawn in Chem draw ultra 8.0 module in Chem office 2004 software and imported into TSAR software. Charges were derived using Charge 2-Derive charges option and optimized by using Cosmic-optimize 3 D option in the structure menu of the project table. Substituent was defined and descriptors were calculated for whole molecule as well as for the substituent. Several equations were generated correlating both Log (% Inh) with physicochemical parameters (descriptors) by multiple linear regression analysis (MLR) method. Data was standardized by range and leave one out method was used for cross validation. Models were excluded if correlation was exceeding 0.9 for more rigorous analysis. Correlation matrix was generated to find any Intercorrelation between the descriptors. Intercorrelation between the descriptors in the final equation is less than 0.2. 1

 

ANTIMICROBIAL SCREENING

Antibacterial activity

The newly synthesized compounds were screened for their antibacterial activity against Escherichia coli (MTCC 443), Bacilus subtilis  (ATCC12228) and Staphylococcus aureus (ATCC25923) bacterial strains by disc diffusion method. In all the determinations tests were performed in triplicate and the results were taken as a mean of three determinations. Ciprofloxacin was used as a standard drug. 2

 

Anti fungal activity

The newly synthesized compounds were screened for their antifungal activity against C. albicans and A. niger in DMSO by agar diffusion method. In all the determinations tests were performed in triplicate and the results were taken as a mean of three determinations. Amphotericin B was used as a standard drug.

 

Anti-tubercular activity

The antitubercular screening was carried out by Middle brook 7H9 agar medium against H37Rv. Strain. Middle brook 7H9 agar medium containing different derivatives, standard drug as well as control, Middle brook 7H9 agar medium was inoculated with Mycobacterium tuberculosis of H37Rv Strain. The inoculated bottles were incubated for 37°C for 4 weeks. At the end of 4 weeks they were checked for growth.3

 

ANTI-INFLAMMATORY ACTIVITY

Carrageenan Induced hind Paw Edema:

Anti-inflammatory activity was carried out by Carrageenan Induced Rat hind Paw method of winter et al. wistar rats (120-150 g) was used for the experiment. The conventional laboratory diet was fed with adequate supply of drinking water. The animals were randomly selected, marked to permit individual identification and kept in polypropylene cages for one week prior to dosing to allow acclimatization of them to laboratory conditions. The drugs were prepared as a suspension by triturating with water and 0.5% sodium CMC. The standard group received 50mg/kg body weight of Ibuprofen, test group received 200mg/kg body weight of synthesized compounds and the control group received 1% w/v of CMC. 4

 

Procedure for Scheme5

Synthesis of 2,4,5- trisubstituted imidazoles  (B1-B12)

0.01 mole of benzyl or ethane dione was mixed with 0.01 mole of aromatic aldehyde along with ammonium acetate and PPA. And refluxed for 3 hrs. Cool pour the reaction mixture on ice to offer solid mass, filtered and recrystallized from hot ethanol to offer titled compounds (B1-B12).


Scheme

 

 


Spectral data:

B1 IR (KBr) cm-1: 3310.4(-CH=CH str.),3213.45 (-NH str.), 3010.23 (Ar-CH str.), 1682.11 (-C=O str.), 1525.32 (-C=N str), 1245.36 (-C-N str). 1H NMR: (δ ppm):   9.06 (CH,4-benzil )

8.0 (NH, sec. amide), 7.26 (CH -imidazole)

 

B2IR (KBr) cm-1: 3310.43 (-CH=CH str.), 3010.23 (Ar-CH str.), 1682.11 (-C=O str.), 1525.32 (-C=N str), 1245.36 (-C-N str). 1H NMR: (δ ppm): 8.3 (CH, benzil 7.26 (CH, imidazole),

 7.04 (CH,4-benzil).

 

B3 IR (KBr) cm-1:  3310.43(-CH=CH str.), 3213.45 (-NH str.), 3010.23 (Ar-CH str.), 1682.11 (-C=O str.), 1525.32 (-C=N str), 1245.36 (-C-N str).   1H NMR: .8 (CL, 7.26 (CH, imidazole),

7.54 (CH, 1-Benzene

B4 IR (KBr) cm-1:  3213.45 (-NH str.), 3010.23 (Ar-CH str.), 1682.11 (-C=O str.), 1525.32 (-C=N str), 1245.36 (-C-N str). 1H NMR: . 8.3 (CH benzil  triazole), 7.26 (CH, -imidazole),

B5  IR (KBr) cm-1:  3010.23 (Ar-CH str.), 1682.11 (-C=O str.), 1525.32 (-C=N str), 1245.36 (-C-N str).   . 1H NMR: . 7.26 (CH, Benz-imidazole), 8.29 (methoxy)

 

B6  IR (KBr) cm-1:  3213.45 (-NH str.), 3010.23 (Ar-CH str.), 1682.11 (-C=O str), 1525.32 (-C=N str), 1245.36 (-C-N str).  6.66 (CH, 1-Benzene 1H NMR: 8.8 (Of OH 7.26 (CH imidazole)

 

B7  IR (KBr) cm-1:   3213.45 (-NH str.), 3010.23 (Ar-CH str.), 1682.11 (-C=O str.), 1525.32 (-C=N str), 1245.36 (-C-N str), 1016.11 (-C-O-C str.).   1H NMR: . .3 (CH)7.26 (CH, imidazole), 6.26 (CH, 1-Benzene), 8.0 (NH, sec. amide)

 

B8 IR (KBr) cm-1:   3010.23 (Ar-CH str.), 1682.11 (-C=O str.), 1525.32 (-C=N str), 1245.36 (-C-N str), 1016.11 (-C-O-C str.).   .   1H NMR: . . 8.3 (CH, 7.26 (CH, imidazole),6.26 (CH, 1-Benzene), 4.0 (NH2, Aromatic C-NH )

 

B9 IR (KBr) cm-1: 3213.45 (-NH str.), 3010.23 (Ar-CH str.), 1682.11 (-C=O str.), 1525.32 (-C=N str), 1245.36 (-C-N str), 1016.11 (-C-O-C str.).      1H NMR: . 8.3 (CH, 7.26 (CH, imidazole), 6.26 (CH, 1-Benzene), 4.0 OF Cl  Aromatic C-NH),  

 

B10  IR (KBr) cm-1:. 3310.23 CH=CH str.), 3010.23 (Ar-CH str.), 1689.78 (-C=O str), 1525.32 (-C=N str), 1245.36 (-C-N str), 1016.38 cm-1(-C-O-C str), 3210.45 (-OH str.), , 3010.23 Ar-CH str.), 1689.78 (-C=O str), 1525.32 (-C=N str), 1245.36 (-C-N str), 1016.38 cm-1(-C-O-C str),        1H NMR: . 7.26 (CH, imidazole), 7.30 (Of OH)

B11  IR (KBr) cm-1:. 3310.23 (-CH=CH str.),3208.12 (-NH2 str. ), 3010.23 (Ar-CH str.), 1689.78 (-C=O str), 1525.32 (-C=N str), 1245.36 (-C-N str), 1016.38 cm-1(-C-O-C str 1H NMR: 7.26 (CH, imidazole), 8.29 (CH,4-pyridine),  6.30 (CH, 1-Benzene), 4.0  of Methoxy

 

B12  IR (KBr) cm-1 3310.23 (-CH=CH str.), 3208.12 (-NH2 str. ), 3210.45 (-OH str.), 3010.23 (Ar-CH str.), 1689.78 (-C=O str), 1525.32 (-C=N str), 1245.36 (-C-N str), 1016.38 cm-1(-C-O-C str),      1H NMR: . 77.26 (CH, imidazole), 8.29 (of Methoxy  6.30 (CH, 1-Benzil ) 4.0 Aromatic C-NH),

 

 


Table no1: Analytical and Physicochemical data of the synthesized compounds  (B1-B12)

Comp.

Mol. Formula

Mol. Wt.

M.P.

° C

Yield

%

Elemental analyses Calcd. (found)

C

H

N

B1

C23H18N2

322

128-132

68

85.68

5.63

8.69

B2

C24H20N2

336

116-118

65

85.68

5.99

8.33

B3

C23H17ClN2

356

202-204

67

77.41

4.80

7.85

B4

C23H18N2O

338

176-178

56

81.63

5.36

8.28

B5

C24H20N2O

352

189-193

58

81.79

5.72

7.95

B6

C23H18N2O

338

207-209

69

81.63

5.36

8.28

B7

C15H18N2

226

210-213

72

79.61

8.02

12.38

B8

C16H20N2

240

235-238

58

79.66

8.39

11.66

B9

C15H17ClN2

260

224-226

71

69.09

6.57

10.74

B10

C15H18N2O

242

175-178

72

74.35

7.49

11.56

B11

C16H20N2O

256

165-169

67

74.97

7.86

10.93

B12

C15H18N2O

242

201-205

64

74.35

7.49

11.56

 

Table no:2  Antibacterial and antifungal activity of synthesized compounds (Scheme-IV)

Compd.

Zone of inhibition at 200µcg/mL (in mm.)

E. coli

B. Subtilis

S. aureus

A. niger

C. albicans

B1

24

25

26

15

22

B2

20

23

25

16

21

B3

20

24

25

19

22

B4

25

26

23

20

21

B5

24

23

26

21

22

B6

20

22

24

18

23

B7

21

23

22

20

21

B8

22

24

25

20

22

B9

23

22

20

18

22

B10

24

26

23

19

21

B11

25

23

24

21

23

B12

26

22

24

20

22

Ciprofloxacin

26

25

26

-

-

Amphotericin B

-

-

-

22

23

 

Table no. 3 : Antitubercular activity of the synthesized compounds

Compd.

25 µcg/mL

50 µcg/mL

100 µcg/mL

B1

R

S

S

B2

R

R

S

B3

R

R

R

B4

R

S

S

B5

R

R

S

B6

R

R

R

B7

R

S

S

B8

R

R

S

B9

R

R

R

B10

R

S

S

B11

R

R

S

B12

R

R

R

Streptomycin

S

S

S

 

Table no.4: Anti-inflammatory activity of Synthesized compounds  (Scheme-IV)

Treatment

Mean increase in paw volume (ml)±SEM

Time in minute

0

% Inh.

30

% Inh.

60

% Inh.

90

% Inh.

120

% Inh.

Carrageenan (Control)

0.21±0.01

 

0.48±0.03

 

0.75±0.09

 

0.85±0.12

 

0.89±0.14

 

Zaltoprofen

0.21±0.03

0

0.28±0.07

32.41

0.27±0.07

58.53

0.24±0.06

66.23

0.23±0.13

67.78

B1

0.21±0.01

0

0.29±0.03

30.33

0.28±0.01

57.25

0.27±0.01

62.88

0.24±0.01

66.66

B2

0.21±0.02

0

0.31±0.03

26.16

0.32±0.01

52.12

0.30±0.01

59.35

0.27±0.02

63.29

B3

0.21±0.01

0

.031±0.01

26.16

0.31±0.01

53.41

0.30±0.02

59.35

0.26±0.02

64.41

B4

0.21±0.02

0

0.38±0.01

11.58

0.45±0.02

35.46

0.49±0.02

38.00

0.39±0.01

49.80

B5

0.20±0.01

3.16

0.29±0.01

30.33

0.28±0.01

57.25

0.28±0.01

62.70

0.26±0.02

65.53

B6

0.21±0.02

0

0.30±0.01

28.25

0.31±0.02

53.41

0.30±0.01

60.35

0.27±0.03

64.41

B7

0.20±0.02

3.16

0.31±0.01

26.16

0.32±0.02

52.12

0.31±0.02

60.17

0.28±0.01

63.29

B8

0.21±0.02

0

0.29±0.02

30.33

0.27±0.03

58.53

0.27±0.02

62.88

0.26±0.02

65.53

B9

0.20±0.03

3.16

0.31±0.02

26.16

0.30±0.01

54.69

0.30±0.02

60.35

0.26±0.02

64.41

B10

0.21±0.01

0

0.31±0.02

26.16

0.31±0.02

53.41

0.29±0.01

61.52

0.28±0.01

63.29

B11

0.21±0.02

0

0.31±0.03

26.16

0.32±0.03

52.12

0.29±0.01

61.52

0.27±0.02

63.29

B12

0.20±0.03

3.16

0.28±0.04

32.41

0.27±0.01

58.53

0.28±0.02

61.70

0.25±0.03

65.53

Inh.=Inhibition

 

Table no. 5 -: Structures and Log (% Inh) of  Compounds


Sr. No.

Comp. Name

Structure

% Inh

Log (% Inh)

1.

B1

 

 

68.47

1.921245

2

B2

 

69.07

1.930762

3.

B3

 

68.09

1.905281

4.

B4

 

72.08

1.928124

5.

B5

 

75.38

1.925689

6.

B6

 

71.04

1.902387

7.

B7

 

72.45

1.928213

8.

B8

 

74.08

1.928945

9.

B9

 

71.57

1.928076

10.

B10

 

72.47

1.923487

11.

B11

 

70.13

1.912367

12

B12

 

72.36

1.923489


RESULTS:

QSAR

Intercorrelation between the descriptors in the final equations is less than 0.2. Best Equations correlating Log (% Inh) with descriptors for series (B1-B12) generated are presented in Table no. 06


 


 

Table no. 6  : Equations generated between Log (% Inh) and descriptors

Sr. No.

Equation

N

S

R

r2

r2cv

F

series

(A1-A9 and B1-B9)

Y = - 0.198 * X3

- 1.478 * X2 – 13.018

12

0.357

0.889

0.598

0.459

13.736

  Where

Y = Log (% Inh)                                        

X1: ClogP      -

X2 = VAMP HOMO (Whole Molecule)

X3 = Dipole Moment Z Component (Whole Molecule)

X4 = Inertia Moment 2 Length (Whole Molecule)

 

Significance of the terms –

N= No. of Molecules

s = standard error --- less is better

r = correlation coefficient – higher is better > 0.7,

r2cv = cross validated r2 - higher is better > 0.5,

F Value = higher is better

Observed and predicted data and graphs are presented in Table no. 06  and Graph I  for Series

 

Table no7 : Observed and predicted log (% Inh) value data for 12 compounds

Comp. No.

Observed Value

Predicted Value

Residual Value

Residual Variance

B1

1.823865

1.92125

0.09738

0.004228

B2

1.801335

1.93076

0.129427

0.004383

B3

1.808953

1.90528

0.096328

0.004398

B4

1.697229

1.92812

0.230895

0.004629

B5

1.81644

1.92569

0.109249

0.003234

B6

1.808953

1.90239

0.093434

0.003264

B7

1.801335

1.92821

0.126878

0.00343

B8

1.81644

1.92895

0.112505

0.00331

B9

1.808953

1.92808

0.119123

0.003333

B10

1.801335

1.92349

0.122152

0.003255

B11

1.801335

1.91237

0.111032

0.003016

B12

1.81644

1.92349

0.107049

0.002865

 

Fig. No 1 : a) Correlation graph and b) Histogram of observed and predicted log (% Inh) data for 12 compounds

 

 


DISCUSSION:

QSAR

Statistical evaluation of the equations is in accepted range. The correlation coefficient is high with less standard error. The residual value and residual variance for each series also is less indicating good predictive power of models. From equation 1 it is observed that two electronic parameters Dipole Moment Z Component (Whole Molecule) and VAMP HOMO (Whole Molecule) contribute (-0.198 and – 1.478) negatively for the activity so electron withdrawing groups may enhance the activity (% Inh).

 

The synthesized derivatives were screened for anti bacterial activity using DMF as a solvent against the organisms S.aureus, B. subtilis and E.coli., and antifungal activity using C. albicans and A. niger by disc diffusion method on nutrient agar media. The standard drug used was Levofloxacin and Amphotericin B for antibacterial and antifungal activity respectively.

 

Antibacterial activity:

The compounds B1,B2,B3,B5,B8, has  excellent Antibacterial activity against S. aureus, the compounds B1,B11,B12 have shown Antibacterial activity against B. subtilis, while B4, B11,B12 shows Antibacterial activity against E.coli., when compared with standard Ciprofloxacin

 

Antifungal activity:

The compounds B5, B11 has  excellent antifungal activity against Aspergillus niger (NCIM 596), while the B1,B3,B5,B6,B8,B9,B11,B12 have shown Antifungal activity against Candida albicans (NCIM 3102) when compared with standard Amphotericin B.

Antitubercular activity:

All the compounds were screened for antitubercular activity by Middle brook 7H9 agar medium as described by Elmer WK et al. against H37Rv Strain. Compounds B1,B7,B10 has shown promising antitubercular activity.

 

Anti-Inflammatory Activity:

All the compounds were evaluated for Anti-inflammatory activity by Carrageenan Induced Rat hind Paw method. The synthesized compounds showed anti-inflammatory activity and it was found comparable with standard drug zaltoprofen.

 

REFERENCES:

1.       Palomer, J.J. Pérez, S. Navea, O. Llorens, J. Pascual, L. García, D. Mauleón,  J. Med. Chem.  43 2280, (2000).

2.       B.Chandrakantha, P.Shetty, V.Nambiyar, Synthesis, Charecterization and biological activity some new 1,3,4 Oxadiazole bearing 2-fluro-4-methoxy phenyl moiety, Europian Journal Medicinal Chemistry,  44, , 1-5, (2009).

3.       Vijay V. Dabholkar and Nitin V. Bhusari, Synthesis of 2-Substituted-1,3,4-Oxadiazole Derivatives, International Journal of Chemical, Environmental and Pharmaceutical Research, Vol. 2, No.1, 1-4 January-April, (2011).

4.       Benmekhbi Lotfi, Bencharif Mustafa, Bencharif Leila, Mosbah Salima, Electrocyclization of Semicarbazone; A Novel Route of Green Synthesis of 2,5-Disubstituted-1,3,4-Oxadiazoles, Int. J. Electrochem. Sci., 6 ,  1991 – 2000, (2011).

5.       K.Mogilaiah,K.Vidya and T.Kumara Swamy ,’’Mild and efficient synthesis of 1,2,4-triazolo [4,3-a][1,8] naphthyridines using Fecl3 in solid state’’. Ind J Chem; 48B:599-601, (2009).

 

 

Received on 07.10.2013       Accepted on 29.11.2013     

© Asian Pharma Press All Right Reserved

Asian J. Pharm. Res. 3(4): Oct. - Dec.2013; Page 159-165